Macrogenics (MGNX) Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Go back to Macrogenics (MGNX) Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer| MACROGENICS (NASDAQ: MGNX) | Delayed: 4.36 -0.04 (0.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.40 | 52 Week High | $36.11 | |||
| Open | $4.29 | 52 Week Low | $14.84 | |||
| Day High | $4.43 | P/E | 11.18 | |||
| Day Low | $4.11 | EPS | $0.39 | |||
| Volume | 205,340 | |||||

